Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CG-806 |
Synonyms | |
Therapy Description |
CG-806 is a small molecule multi-kinase inhibitor that inhibits both wild-type and mutant Flt3 and Btk, resulting in growth inhibition in tumor cells (PMID: 38871487). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CG-806 | CG'806|CG-026806|CG806|Luxeptinib | BTK inhibitor 37 FLT3 Inhibitor 69 | CG-806 is a small molecule multi-kinase inhibitor that inhibits both wild-type and mutant Flt3 and Btk, resulting in growth inhibition in tumor cells (PMID: 38871487). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 wild-type | acute myeloid leukemia | predicted - sensitive | CG-806 | Preclinical - Cell culture | Actionable | In a preclinical study, CG-806 inhibited Btk and aurora kinase activation, induced G2/M arrest and autophagy in acute myeloid leukemia cells harboring wild-type FLT3 in culture (Blood 2017 130:4629). | detail... |
FLT3 exon 14 ins | acute myeloid leukemia | sensitive | CG-806 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CG-806 inhibited downstream signaling, induced apoptosis, and inhibited proliferation of acute myeloid leukemia cell lines harboring a FLT3 exon 14 insertion (ITD) mutation in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 35499387). | 35499387 |
FLT3 D835Y | hematologic cancer | sensitive | CG-806 | Preclinical - Cell culture | Actionable | In a preclinical study, CG-806 inhibited proliferation of a cell line expressing FLT3 D835Y in culture (PMID: 35499387). | 35499387 |
FLT3 exon 14 ins FLT3 D835Y | hematologic cancer | sensitive | CG-806 | Preclinical - Cell culture | Actionable | In a preclinical study, CG-806 inhibited proliferation of a cell line expressing a FLT3 exon 14 insertion (ITD) mutation and FLT3 D835Y in culture (PMID: 35499387). | 35499387 |
FLT3 exon 14 ins | hematologic cancer | sensitive | CG-806 | Preclinical - Cell culture | Actionable | In a preclinical study, CG-806 inhibited proliferation of a cell line expressing a FLT3 exon 14 insertion (ITD) mutation in culture (PMID: 35499387). | 35499387 |
IDH1 R132X | acute myeloid leukemia | predicted - sensitive | CG-806 | Preclinical - Patient cell culture | Actionable | In a preclinical study, patient-derived acute myeloid leukemia cells harboring IDH1 R132X mutations demonstrated increased sensitivity to CG-806 compared to wild-type cells in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1323). | detail... |
FLT3 exon 14 ins FLT3 F691L | hematologic cancer | sensitive | CG-806 | Preclinical - Cell culture | Actionable | In a preclinical study, CG-806 inhibited proliferation of a cell line expressing a FLT3 exon 14 insertion (ITD) mutation and FLT3 F691L in culture (PMID: 35499387). | 35499387 |
TP53 mutant | acute myeloid leukemia | predicted - sensitive | CG-806 | Preclinical - Patient cell culture | Actionable | In a preclinical study, patient-derived acute myeloid leukemia cells harboring TP53 mutations were sensitive to CG-806 in culture (Proceedings of the American Association for Cancer Research, Vol 60, Mar 2019, Abstract #1323). | detail... |
TP53 mutant | chronic lymphocytic leukemia | predicted - sensitive | CG-806 | Case Reports/Case Series | Actionable | In a Phase I trial, CG-806 treatment was well-tolerated, and a patient with chronic lymphocytic leukemia harboring a TP53 mutation stayed on treatment for more than 8 cycles (25th Annual Congress of EHA (Jun 2020), Abstract EP711; NCT03893682). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04477291 | Phase Ib/II | CG-806 | A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Active, not recruiting | USA | 0 |
NCT03893682 | Phase I | CG-806 | A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas | Active, not recruiting | USA | 0 |